Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
59.65
+0.64 (1.08%)
Sep 3, 2026, 4:00 PM EDT - Market closed
Enliven Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 135.51 | 98.9 | 124.12 | 100.14 | 75.54 | 110.02 |
Short-Term Investments | 759.65 | 363.73 | 189.32 | 153.01 | - | - |
Cash & Short-Term Investments | 895.16 | 462.62 | 313.44 | 253.15 | 75.54 | 110.02 |
Cash Growth | 82.50% | 47.59% | 23.82% | 235.14% | -31.35% | -15.60% |
Prepaid Expenses | 12.18 | 12.26 | 4.63 | 2.95 | 2.22 | 0.65 |
Restricted Cash | - | - | 0.05 | 0.05 | - | - |
Other Current Assets | - | - | - | 10 | - | - |
Total Current Assets | 907.34 | 474.88 | 318.13 | 266.15 | 77.75 | 110.67 |
Property, Plant & Equipment | 1.64 | 0.42 | 0.46 | 1.06 | 1.52 | 0.95 |
Long-Term Deferred Charges | - | 0.22 | - | 0.56 | 3.98 | 1.65 |
Other Long-Term Assets | 1.24 | 0.66 | 7.18 | 4.09 | 0.05 | 0.05 |
Total Assets | 910.22 | 476.17 | 325.76 | 271.87 | 83.3 | 113.33 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.37 | 2.16 | 1.34 | 0.53 | 3.44 | 2.52 |
Accrued Expenses | 13.06 | 13.66 | 14.37 | 14.66 | 4.32 | 2.84 |
Current Portion of Leases | 0.6 | 0.4 | - | 0.34 | 0.32 | 0.16 |
Other Current Liabilities | 0.13 | 0.35 | 0.2 | 10.36 | 1.64 | 0.23 |
Total Current Liabilities | 14.16 | 16.57 | 15.92 | 25.89 | 9.72 | 5.75 |
Long-Term Leases | 0.91 | - | - | - | 0.28 | - |
Other Long-Term Liabilities | - | - | - | 0.07 | 0.38 | 0.71 |
Total Liabilities | 15.07 | 16.57 | 15.92 | 25.96 | 10.37 | 6.47 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.07 | 0.06 | 0.05 | 0.04 | 0 | 0 |
Additional Paid-In Capital | 1,300 | 806.37 | 553.21 | 400.17 | 6.04 | 2.31 |
Retained Earnings | -403.28 | -347.17 | -243.47 | -154.45 | -82.86 | -45.2 |
Comprehensive Income & Other | -1.91 | 0.33 | 0.06 | 0.14 | - | - |
Total Common Equity | 895.15 | 459.6 | 309.85 | 245.91 | -76.83 | -42.89 |
Shareholders' Equity | 895.15 | 459.6 | 309.85 | 245.91 | 72.92 | 106.86 |
Total Liabilities & Equity | 910.22 | 476.17 | 325.76 | 271.87 | 83.3 | 113.33 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.51 | 0.4 | - | 0.34 | 0.6 | 0.16 |
Net Cash (Debt) | 893.65 | 462.22 | 313.44 | 252.81 | 74.94 | 109.87 |
Net Cash Growth | 82.41% | 47.47% | 23.98% | 237.37% | -31.79% | -15.66% |
Net Cash Per Share | 14.10 | 8.16 | 6.66 | 7.11 | 23.99 | 14.06 |
Filing Date Shares Outstanding | 73.27 | 59.8 | 49 | 41.35 | 12.1 | 11.64 |
Total Common Shares Outstanding | 73.25 | 59.44 | 48.94 | 41.29 | 12.1 | 11.64 |
Working Capital | 893.18 | 458.31 | 302.21 | 240.26 | 68.04 | 104.92 |
Book Value Per Share | 12.22 | 7.73 | 6.33 | 5.96 | -6.35 | -3.68 |
Tangible Book Value | 895.15 | 459.6 | 309.85 | 245.91 | -76.83 | -42.89 |
Tangible Book Value Per Share | 12.22 | 7.73 | 6.33 | 5.96 | -6.35 | -3.68 |
Machinery | 0.39 | 0.26 | 1.38 | 1.41 | 1.26 | 0.65 |